Your browser doesn't support javascript.
loading
Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors.
Pin, Alessia; Tesser, Alessandra; Pastore, Serena; Moressa, Valentina; Valencic, Erica; Arbo, Anna; Maestro, Alessandra; Tommasini, Alberto; Taddio, Andrea.
Afiliação
  • Pin A; Department of Pediatrics, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Tesser A; Department of Pediatrics, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Pastore S; Department of Pediatrics, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Moressa V; Department of Pediatrics, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Valencic E; Department of Pediatrics, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Arbo A; Department of Pharmacy and Clinical Pharmacology, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Maestro A; Department of Pharmacy and Clinical Pharmacology, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Tommasini A; Department of Pediatrics, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
  • Taddio A; Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy.
Int J Mol Sci ; 21(20)2020 Oct 20.
Article em En | MEDLINE | ID: mdl-33092242
ABSTRACT
Off-label use of medications is still a common practice in pediatric rheumatology. JAK inhibitors are authorized in adults in the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Although their use is not authorized yet in children, JAK inhibitors, based on their mechanism of action and on clinical experiences in small series, have been suggested to be useful in the treatment of pediatric interferon-mediated inflammation. Accordingly, an increased interferon score may help to identify those patients who might benefit of JAK inhibitors. We describe the clinical experience with JAK inhibitors in seven children affected with severe inflammatory conditions and we discuss the correlation between clinical features and transcriptomic data. Clinical improvements were recorded in all cases. A reduction of interferon signaling was recorded in three out of seven subjects at last follow-up, irrespectively from clinical improvements. Other signal pathways with significant differences between patients and controls included upregulation of DNA repair pathway and downregulation of extracellular collagen homeostasis. Two patients developed drug-related adverse events, which were considered serious in one case. In conclusion, JAK inhibitors may offer a valuable option for children with severe interferon-mediated inflammatory disorders reducing the interferon score as well as influencing other signal pathways that deserve future studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Perfilação da Expressão Gênica / Uso Off-Label / Inibidores de Janus Quinases / Inflamação Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: Int J Mol Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Perfilação da Expressão Gênica / Uso Off-Label / Inibidores de Janus Quinases / Inflamação Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: Int J Mol Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália